Market capitalization | $89.50m |
Enterprise Value | $10.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 92.73 |
P/S ratio (TTM) P/S ratio | 813.64 |
P/B ratio (TTM) P/B ratio | 1.02 |
Revenue (TTM) Revenue | $110.00k |
EBIT (operating result TTM) EBIT | $-57.27m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a InflaRx N.V. forecast:
5 Analysts have issued a InflaRx N.V. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.11 0.11 |
-
|
|
Gross Profit | -1.30 -1.30 |
-
|
|
EBITDA | -57 -57 |
-
|
EBIT (Operating Income) EBIT | -57 -57 |
-
|
Net Profit | -51 -51 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Head office | Netherlands |
CEO | Niels Riedemann |
Employees | 66 |
Founded | 2007 |
Website | www.inflarx.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.